trending Market Intelligence /marketintelligence/en/news-insights/trending/0dkyahw-qe1jqwritu52xw2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Takeda to invest €10M in TiGenix

L.K. Bennett: Bankruptcy Case Study

State Of Singapore Online Video Subscription

Power Forecast Briefing: Capacity Shortfalls to Test the Renewable Energy Transition

Episode 43 - More Change, M&A On Horizon For Equity Research Industry


Takeda to invest €10M in TiGenix

TiGenix NV exercised an option to issue shares to Takeda Pharmaceutical Co. Ltd.

The company will issue 11,651,778 shares at 85.8 euro cents apiece for an equity investment of €10 million.

Takeda owns the rights to TiGenix's Cx601 drug for the treatment of Crohn's disease outside the U.S.

"These additional funds will further strengthen our financial position allowing us to remain fully focused on progressing with the marketing authorization application of Cx601 in Europe, the launch of our Phase III trial to register Cx601 in the United States and advancing with the other clinical assets in our pipeline," TiGenix CEO Eduardo Bravo said in a statement.

The new shares will be issued in early January.